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6.27 (95% CI 4.93–7.98). Dichotomizing the material according to
CSF T-tau or P-tau did not change the ORs as compared with
clinical diagnosis only (Figure 1). Even though the OR for the ratio
P-tau/Ab42 (6.50 (95% CI 5.07–8.35)) was slightly higher than for
Ab42 alone, the difference was not statistically significant.
We also compared patients, again disregarding the clinical
diagnoses, who had a complete CSF biomarker signature
indicative of AD, that is, low Ab42 and both high T-tau and
P-tau (n¼ 438, see Supplementary Material for a detailed
description of the signature), with subjects with a negative CSF
biomarker pattern (n¼ 414). The biomarker diagnosis strength-
ened the association to APOE e4; the OR increased from 4.45 (95%
CI 3.52–5.62) in pure clinical diagnosis to 7.66 (95% CI 5.65–10.39)
in patients classified on the basis of biomarker data alone.
Finally, ORs were calculated on subjects having both a clinical
diagnosis and a concordant complete biomarker profile
(n(AD)¼ 324; n(control)¼ 155). This approach resulted in an
even stronger association of APOE e4 with AD (OR 10.4, 95% CI
6.65–16.3). Similar effects were seen when comparing non-carriers
with e4 heterozygotes and homozygotes across the different
diagnostic groups (Figure 1, Supplementary Material).
These results have several important implications. First, APOE e4
appears as strongly associated with amyloid pathology as clinical
AD. Second, clinical criteria that incorporate biomarker informa-
tion on Alzheimer’s pathology give a stronger association
with APOE e4 than clinical diagnosis alone. This is compatible
with the presumed higher diagnostic accuracy of the revised
clinical approach,1–3 and has also been seen in a series of
neuropathologically verified AD cases and controls.7 Third, the
approach of combining clinical with biomarker data may increase
the power of genetic association studies, as well as the potential
to provide insights into the mechanistic pathways through which
genetic risk factors may exert their effects.
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The inflammation hypothesis of depression, or more broadly,
common mental disorders, proposes that chronic inflammation
plays an important role in the pathophysiology of these
conditions.1,2 The hypothesis is supported by experiments of
inflammatory stimuli, antidepressant trials and studies on
depression-related genes and pathogen host defense,2–5 but
direct population-based evidence from long-term inflammation is
scarce. Because of a lack of studies on the effects of chronically
elevated inflammation, assessed over several years using repeat
measurements, it has remained unclear whether the association
between inflammation and common mental disorder is the
consequence of acute or chronic inflammation.
This report is from the Whitehall II cohort study.6 In our analysis
of up to 4630 adults without chronic disease, we used repeat
measures of inflammatory markers and mental disorder. We
measured the proinflammatory cytokine interleukin 6 (IL-6) in
1992, 1997 and 2003 and common mental disorder, based on
the General Health Questionnaire (GHQ), in 1997, 2003 and
2008. The IL-6 distribution was categorized as:p1.0 pgml 1 (low),
1.1–2.0 pgml 1 (intermediate) and 42.0 pgml 1 (high). Details
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of study designs, methods and the included/excluded study
populations are presented in Supplementary Material, Supplemen-
tary Figures S1-S4 and Supplementary Tables S1 and S2.
Cross-sectional analysis, using data from 1997, showed IL-6 not to
be associated with common mental disorder (age- and sex-adjusted
odds ratio for high versus low IL-6¼ 1.04 (95% CI 0.85–1.27),
P¼ 0.69, Study Design A). Then we examined the cumulative 10-
year risk of common mental disorder among the 2757 participants
without the disorder at the first GHQ assessment in 1997.
Compared to participants with low IL-6 in 1997, those with high
IL-6 had a greater likelihood of common mental disorder in 2003
and/or 2008 (a total of 549 new cases) (age- and sex-adjusted odds
ratio¼ 1.40 (1.07–1.82), P¼ 0.01) (Figure 1, Study Design B).
Furthermore, participants with high IL-6 at both the 1992 and
1997 assessments had higher odds of a new-onset mental disorder
in 2003 and/or 2008, 1.61 (1.14–2.28, P¼ 0.007, Figure 1), with the
odds ratio being even higher, 1.75 (1.19–2.57, P¼ 0.004), among
those who had high IL-6 in 1992, 1997 and 2003.
To further examine dose–response associations, we used the
number of times a participant had IL-642 pgml 1 as the
exposure (Study Design B). Results show that those demonstrating
high IL-6 on 0, 1, 2 and 3 occasions had odds ratios of 1.00
(reference), 1.18 (0.94–1.47), 1.38 (1.04–1.83) and 1.56 (1.10–2.21),
respectively, for a 10-year risk of common mental disorder (total
N¼ 2757; Ptrend¼ 0.002).
Multivariable adjusted results and the sensitivity analyses in
Supplementary Table S3 (Study Design C) show that the
association between the 5-year average level of IL-6 and
subsequent 10-year risk of common mental disorder was little
affected by adjustments for acute inflammation, obesity, smoking
and drug treatments. The relationship between IL-6 and common
mental disorder was evident in both men (odds ratio per doubling
of IL-6¼ 1.46 (1.19–1.78)) and women (1.34 (1.00–1.79)), and there
was no statistical evidence of sex difference in this relationship
(Psex interaction¼ 0.67).
In the subgroup of participants without common mental
disorder at the third inflammation measurement (2003, Study
Design D), odds ratio of new common mental disorder in 2008 for
high IL-6 in 1992, 1997 and 2003 was 1.42 (0.78–2.57) (details in
Supplementary Material).
These findings support the hypothesis that persistently elevated
levels of IL-6 contribute to the development of common mental
disorder.1,2 The fact that previous studies relied on a single
measurement of IL-6 may partially explain the mixed findings:7 a
one-off measure does not reliably capture the chronicity of
inflammation.8 The present study has limitations: common mental
disorder measured by a questionnaire is not the same as clinical
diagnosis of depression or anxiety.9 Our data are from an
occupational cohort where participants are likely to be healthier
than the general population. Loss to follow-up accumulated over
the extended follow-up; however, there was no evidence of major
differences between the analytic sample and the sample at study
recruitment.
Our findings have important clinical implications. If the
observed association is causal, then targeting chronic inflamma-
tion with anti-inflammatory drugs could be useful in prevention of
common mental disorder. Further studies are needed to clarify the
underlying mechanisms, such as activation of the tryptophan-
degrading enzyme, changes in indoleamine 2,3-dioxygenase, and
abnormalities of the hypothalamic–pituitary–adrenal axis. Future
investigations should also test the side effects, since anti-
inflammatory strategies might increase the risk of infection and
malignancy.10
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Figure 1. Interleukin 6 (IL-6) and common mental disorder in the
Whitehall II study of British civil servants. The figure shows that the
increased 10-year risk of common mental disorder associated with
high IL-6 levels is more marked when the assessment of IL-6 is based
on repeat measurements (age- and sex-adjusted odds ratio¼ 1.61
(95% CI: 1.14–2.28)) than a single measurement (age- and sex-
adjusted odds ratio¼ 1.40 (95% CI: 1.07–1.82)). *Po0.05, **Po0.01.
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